Cargando…

Development and Characterization of Cyclodextrin-Based Nanogels as a New Ibuprofen Cutaneous Delivery System

Nanogels combine the properties of hydrogels and nanocarrier systems, resulting in very effective drug delivery systems, including for cutaneous applications. Cyclodextrins (CDs) have been utilised to enhance the nanogels’ loading ability towards poorly soluble drugs and promote/sustain drug release...

Descripción completa

Detalles Bibliográficos
Autores principales: Cirri, Marzia, Nerli, Giulia, Mennini, Natascia, Maestrelli, Francesca, Mura, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788478/
https://www.ncbi.nlm.nih.gov/pubmed/36559061
http://dx.doi.org/10.3390/pharmaceutics14122567
_version_ 1784858763471093760
author Cirri, Marzia
Nerli, Giulia
Mennini, Natascia
Maestrelli, Francesca
Mura, Paola
author_facet Cirri, Marzia
Nerli, Giulia
Mennini, Natascia
Maestrelli, Francesca
Mura, Paola
author_sort Cirri, Marzia
collection PubMed
description Nanogels combine the properties of hydrogels and nanocarrier systems, resulting in very effective drug delivery systems, including for cutaneous applications. Cyclodextrins (CDs) have been utilised to enhance the nanogels’ loading ability towards poorly soluble drugs and promote/sustain drug release. However, formation of CD-based nanogels requires the use of specially modified CDs, or of crosslinking agents. The aim of this work was to develop a CD-based nanogel to improve the cutaneous delivery of ibuprofen by using the soluble β-cyclodextrin/epichlorohydrin polymer (EPIβCD) without adding any potentially toxic crosslinker. The use of EPIβCD enabled increasing ibuprofen loading due to its complexing/solubilizing power towards the poorly soluble drug and prolonging drug release over time due to the nanogel formation. DLS analysis proved that EPIβCD allowed the formation of nanostructures ranging from 60 up to 400 nm, depending on the gelling agent type and the gel preparation method. EPIβCD replacement with monomeric HPβCD did not lead in any case to nanogel formation. Permeation experiments using skin-simulating artificial membranes proved that the EPIβCD-based nanogel enhanced ibuprofen solubility and release, increasing its permeation rate up to 3.5 times, compared to a reference formulation without CD and to some commercial gel formulations, and also assured a sustained release. Moreover, EPIβCD replacement with HPβCD led to a marked increase in drug solubility and initial release rate, but did not provide a prolonged release due to the lack of a nano-matrix structure controlling drug diffusion.
format Online
Article
Text
id pubmed-9788478
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97884782022-12-24 Development and Characterization of Cyclodextrin-Based Nanogels as a New Ibuprofen Cutaneous Delivery System Cirri, Marzia Nerli, Giulia Mennini, Natascia Maestrelli, Francesca Mura, Paola Pharmaceutics Article Nanogels combine the properties of hydrogels and nanocarrier systems, resulting in very effective drug delivery systems, including for cutaneous applications. Cyclodextrins (CDs) have been utilised to enhance the nanogels’ loading ability towards poorly soluble drugs and promote/sustain drug release. However, formation of CD-based nanogels requires the use of specially modified CDs, or of crosslinking agents. The aim of this work was to develop a CD-based nanogel to improve the cutaneous delivery of ibuprofen by using the soluble β-cyclodextrin/epichlorohydrin polymer (EPIβCD) without adding any potentially toxic crosslinker. The use of EPIβCD enabled increasing ibuprofen loading due to its complexing/solubilizing power towards the poorly soluble drug and prolonging drug release over time due to the nanogel formation. DLS analysis proved that EPIβCD allowed the formation of nanostructures ranging from 60 up to 400 nm, depending on the gelling agent type and the gel preparation method. EPIβCD replacement with monomeric HPβCD did not lead in any case to nanogel formation. Permeation experiments using skin-simulating artificial membranes proved that the EPIβCD-based nanogel enhanced ibuprofen solubility and release, increasing its permeation rate up to 3.5 times, compared to a reference formulation without CD and to some commercial gel formulations, and also assured a sustained release. Moreover, EPIβCD replacement with HPβCD led to a marked increase in drug solubility and initial release rate, but did not provide a prolonged release due to the lack of a nano-matrix structure controlling drug diffusion. MDPI 2022-11-23 /pmc/articles/PMC9788478/ /pubmed/36559061 http://dx.doi.org/10.3390/pharmaceutics14122567 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Cirri, Marzia
Nerli, Giulia
Mennini, Natascia
Maestrelli, Francesca
Mura, Paola
Development and Characterization of Cyclodextrin-Based Nanogels as a New Ibuprofen Cutaneous Delivery System
title Development and Characterization of Cyclodextrin-Based Nanogels as a New Ibuprofen Cutaneous Delivery System
title_full Development and Characterization of Cyclodextrin-Based Nanogels as a New Ibuprofen Cutaneous Delivery System
title_fullStr Development and Characterization of Cyclodextrin-Based Nanogels as a New Ibuprofen Cutaneous Delivery System
title_full_unstemmed Development and Characterization of Cyclodextrin-Based Nanogels as a New Ibuprofen Cutaneous Delivery System
title_short Development and Characterization of Cyclodextrin-Based Nanogels as a New Ibuprofen Cutaneous Delivery System
title_sort development and characterization of cyclodextrin-based nanogels as a new ibuprofen cutaneous delivery system
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788478/
https://www.ncbi.nlm.nih.gov/pubmed/36559061
http://dx.doi.org/10.3390/pharmaceutics14122567
work_keys_str_mv AT cirrimarzia developmentandcharacterizationofcyclodextrinbasednanogelsasanewibuprofencutaneousdeliverysystem
AT nerligiulia developmentandcharacterizationofcyclodextrinbasednanogelsasanewibuprofencutaneousdeliverysystem
AT mennininatascia developmentandcharacterizationofcyclodextrinbasednanogelsasanewibuprofencutaneousdeliverysystem
AT maestrellifrancesca developmentandcharacterizationofcyclodextrinbasednanogelsasanewibuprofencutaneousdeliverysystem
AT murapaola developmentandcharacterizationofcyclodextrinbasednanogelsasanewibuprofencutaneousdeliverysystem